|

Antihistamine for Prevention of HTR After Blood Primed CPB

RECRUITINGPhase 4Sponsored by Kasr El Aini Hospital
Actively Recruiting
PhasePhase 4
SponsorKasr El Aini Hospital
Started2026-03-01
Est. completion2026-11
Eligibility
Age1 Year – 7 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07536152

Summary

This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included. The patients will be randomly allocated (20 patients per group) to receive a single intravenous dose of combined chlorpheniramine or normal saline immediately after separation from CPB, before protamine administration.

Eligibility

Age: 1 Year – 7 YearsHealthy volunteers accepted
Inclusion Criteria:

* Acyanotic congenital heart disease.
* Age :1 -7 years.
* Genre: both.

Exclusion Criteria:

* Redo patient.
* History of allergy to antihistamines.
* Bleeding disorders with INR \> 1.5 and/or platelets \< 50,000.
* Emergency procedure.

Conditions2

Blood Transfusion Associated Adverse ReactionsHeart Disease

Interventions1

Antihestamine

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.